A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

Relapse/Refractory Multiple Myeloma Clinical Trial

— MARCH  

Official title:

An Open-Label, Single-Arm Study of ATG-010 Plus Dexamethasone in Patients With Multiple Myeloma Refractory to Prior Treatment With Immunomodulatory Agents and Proteasome Inhibitor

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03944057
• Other study ID #: ATG-010-MM-001
• Status: Completed
• Phase: Phase 2
• Start date: September 2, 2019
• Est. completion date: February 25, 2022

Study information

• Verified date: May 2023
• Source: Antengene Corporation
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.

Description:

This is a single-arm, open-label, multicenter study of ATG-010 (Selinexor) plus low dose Dexamethasone dosed twice weekly each week in four-week cycles, in patients with triple-refractory MM. The population refractory for the primary efficacy analysis will contain only patients with triple-MM enrolled. PK analysis would be performed which would contain approximately 30% of the patients enrolled. Safety analyses will be performed on the overall population of patients who received at least one dose of study drug among triple-refractory patient populations. Patients will receive treatment until progressive disease (PD), death, toxicity that cannot be managed by standard care, or withdrawal, whichever occurs first.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: February 25, 2022
• Est. primary completion date: February 25, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Written informed consent in accordance with federal, local, and institutional guidelines.

2. Age = 18 years at the time of signing informed consent.

3. Patients must have previously received including proteasome inhibitors (PI) (i.e., lenalidomide) and immunomodulatory drugs (i.e., bortezomib) and were refractory to both drugs.

4. Any clinically significant non-hematological toxicities (except for peripheral neuropathy as described in exclusion criterion #17) that patients experienced from treatments in previous clinical studies must have resolved to Grade = 2 by Cycle 1 Day 1.

5. Adequate hepatic function within 21 days prior to Cycle 1 Day 1: total bilirubin < 2x upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3x ULN), AST < 2.5x ULN and ALT < 2.5x ULN.

6. Adequate renal function within 21 days prior to Cycle 1 Day 1: estimated creatinine clearance of = 20 mL/min, calculated using the formula of cockroft and gault.

7. Eastern Cooperative Oncology Group (ECOG) Performance Status of = 2.

8. Measurable MM based on IMWG guidelines.

9. Adequate hematopoietic function within 21 days prior to Cycle 1 Day 1 (See Exclusion Criterion #20 for transfusion washout periods for RBCs and platelets):

1. Hemoglobin level = 8.5 g/dL

2. ANC = 1000/mm^3

3. Platelet count = 75,000/mm^3 (patients in whom < 50% of bone marrow nucleated cells are plasma cells) or = 50,000/mm^3 (patients in whom = 50% of bone marrow nucleated cells are plasma cells. [Platelet transfusions < 1 week prior to Cycle 1 Day 1 are prohibited (see below).]

10. Female subjects of child-bearing potential must have both of the following:

1. Agree to the use of two study physician-approved contraceptive methods simultaneously, or practice complete abstinence starting at the time of ICF signature, while on study medication, and 3 months following the last dose of study drug.

2. Have negative serum pregnancy test result at screening.

Exclusion Criteria:

• The presence of any of the following will exclude a subject from enrollment:

1. Active smoldering MM.

2. Active plasma cell leukemia.

3. Documented systemic amyloid light chain amyloidosis.

4. Active central nervous system (CNS) MM.

5. Pregnancy or breastfeeding.

6. Chemotherapy = 4 week, radiation and immunotherapy = 4 weeks prior to Cycle 1 Day 1, and radio-immunotherapy 6 weeks prior to Cycle 1 Day 1.

7. Active graft vs. host disease (after allogeneic stem cell transplantation) at Cycle 1 Day 1

8. Life expectancy of < 4 months.

9. Major surgery within four weeks prior to Cycle 1 Day 1.

10. Active, unstable cardiovascular function:

1. Symptomatic ischemia, or

2. Uncontrolled clinically-significant conduction abnormalities (e.g., patients with ventricular tachycardia on antiarrhythmics are excluded; patients with 1st degree atrioventricular (AV) block or asymptomatic left anterior fascicular block/right bundle branch block (LAFB/RBBB) will not be excluded), or

3. Congestive heart failure (CHF) of New York Heart Association (NYHA) Class = 3, or

4. Myocardial infarction (MI) within 3 months prior to Cycle 1 Day 1.

11. Prior exposure to a SINE compound, including ATG-010.

Related Conditions & MeSH terms

• Multiple Myeloma
• Neoplasms, Plasma Cell
• Relapse/Refractory Multiple Myeloma

Intervention

Drug:
• ATG-010
ATG-010 (Selinexor) will be given at an oral fixed milligram (mg) dose of 80 mg twice weekly each week for four-week cycles (total of 8 ATG-010 doses per cycle). Dexamethasone 20 mg will be given with each dose of ATG-010 (Selinexor)

Locations

Country	Name	City	State
China	Beijing Chao-Yang Hospital, Capital Medical University	Beijing	Beijing
China	Peking University Third Hospital	Beijing	Beijing
China	The First Bethune Hospital of Jilin University	Changchun	Jilin
China	The Third Xiangya Hospital of Central Suoth University	Changsha	Hunan
China	Guangdong Provincial Peoples Hospital	Guangzhou	Guangdong
China	Nanfang Hospital	Guangzhou	Guangdong
China	Sun Yat-Sen University Cancer Center	Guanzhou	Guangdong
China	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang
China	The First Affiliated Hospital of Nanchang University	Nanchang	Jiangxi
China	The First Affilate Hospital with Nanjing Medical University	Nanjing	Jiangsu
China	Shanghai Changzheng Hospital	Shanghai	Shanghai
China	Shanghai Sixth People's Hospital Affiliate Shanghai JiaoTong University	Shanghai	Shanghai
China	Shengjing Hospital of China Medical University	Shenyang	Liaoning
China	The First Affiliated Hospital of Soochow University	Suzhou	Jiangsu
China	Tianjin blood research institute	Tianjin	Tianjin
China	Xijing Hospital	Xi'an	Shanxi
China	Henan Cancer Hospital	Zhengzhou	Henan

Sponsors (1)

Lead Sponsor	Collaborator
Antengene Corporation

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall Response Rate (ORR)	The primary efficacy endpoint of ORR consists of proportion of patients who achieve PR, VGPR, CR, or sCR according to IMWG 2016 criteria: CR means Negative IFE of serum and urine, disappearance of any soft tissue plasmacytomas (SPD), and <5% plasma cells in bone marrow aspirates; sCR means CR as defined above plus normal FLC ratio and absence of clonal cells in bone marrow biopsy by immunohistochemistry (?/? ratio = 4:1 or = 1:2 for ? and ? patients, respectively, after counting = 100 plasma cells); VGPR means Serum and urine M-protein detectable by IFE but not on electrophoresis, or =90% reduction in serum M-protein plus urine M-protein level <100 mg per 24 hours; PR means =50% reduction of serum M-protein plus reduction in 24-hour urine M-protein by =90% or to <200 mg per 24 hours. If the serum and urine M-protein are unmeasurable, a =50% decrease in the difference between involved and uninvolved FLC levels is required in place of the M-protein criteria.	12 months
Secondary	Progression-Free Survival (PFS)	To evaluate progression-free survival	12 months